Literature DB >> 11247786

Assessment of segmental wall motion abnormalities using contrast two-dimensional echocardiography in awake mice.

K Suehiro1, S Takuma, C Cardinale, T Hozumi, J Shimizu, H Yano, M R Di Tullio, J Wang, C R Smith, D Burkhoff, S Homma.   

Abstract

Murine models of cardiac disease are becoming an important tool for studying pathophysiological processes. Development of methods to accurately assess ventricular function are therefore important. The purpose of this study was to evaluate the feasibility of echocardiographic assessment of segmental wall motion abnormalities in a murine model of myocardial infarction. Two-dimensional contrast (C+) and noncontrast (C-) echocardiography were performed in 76 awake mice 2 days before and 2 days after left coronary ligation. The short-axis images obtained with two-dimensional echocardiography and corresponding postmortem cross-sectional histological samples stained with Evans blue dye were each divided into 16 segments, and all matched segments were examined for correlation between wall motion abnormalities and myocardial hypoperfusion. With the use of contrast enhancement, the number of visualized segments was significantly increased (base: C- 86%, C+ 98%; midpapillary: C- 57%, C+ 89%; apex: C- 30%, C+ 74%). Agreement between echocardiographically assessed regional wall motion abnormalities and pathologically determined hypoperfusion in basal, midpapillary, and apical levels were 90%, 93%, and 93%, respectively. Agreement between echocardiographically normal wall motion and pathologically normal findings in basal, midpapillary, and apical levels were 99%, 88%, and 71%, respectively. Thus echocardiographic assessment of segmental wall motion in awake mice was feasible and the accuracy was improved with the use of a contrast agent.

Entities:  

Mesh:

Year:  2001        PMID: 11247786     DOI: 10.1152/ajpheart.2001.280.4.H1729

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  4 in total

1.  Echocardiographic assessment of the right heart in mice.

Authors:  Evan Brittain; Niki L Penner; James West; Anna Hemnes
Journal:  J Vis Exp       Date:  2013-11-27       Impact factor: 1.355

2.  Simvastatin preserves cardiac function in genetically determined cardiomyopathy.

Authors:  Seena S Abraham; Juan C Osorio; Shunichi Homma; Jie Wang; Harshwardhan M Thaker; James K Liao; Seema Mital
Journal:  J Cardiovasc Pharmacol       Date:  2004-03       Impact factor: 3.105

3.  Myocardial infarct size and area at risk assessment in mice.

Authors:  Bjorn Redfors; Yangzhen Shao; Elmir Omerovic
Journal:  Exp Clin Cardiol       Date:  2012

4.  Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor.

Authors:  Juan C Osorio; Faisal H Cheema; Timothy P Martens; Naila Mahmut; Caroline Kinnear; Ana M D Gonzalez; William Bonney; Shunichi Homma; James K Liao; Seema Mital
Journal:  Can J Physiol Pharmacol       Date:  2008-09       Impact factor: 2.273

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.